Tracking the Evolution of Non‐Small‐Cell Lung Cancer

By M. Jamal-Hanjani, G. Wilson, Nicholas McGranahan, Nicolai J. Birkbak, T. Watkins, S. Veeriah, S. Shafi, Diana H. Johnson, R. Mitter, R. Rosenthal and 73 more. New England Journal of Medicine, 2017

2,016 citations recorded by the source corpus.

Subfields: Cancer Research, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/6d57cc74fd2259762069bca2bcde2ae36d3a76dd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Hugo J. W. L. Aerts
2. Charles Swanton
3. Ahmed Hosny
4. A. Marusyk
5. K. Polyak
6. Lawrence Loeb
7. Aadel A Chaudhuri
8. Robert B. West

In Pulmonary and Respiratory Medicine

1. Ahmed Hosny
2. Hugo J. W. L. Aerts
3. Charles Swanton
4. Matthew B. Schabath

Citations in the corpus

• Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic (2018, background): “deaminase family and can also occur following cytotoxic chemotherapy in resistant emergent subclones [54-57].”
• Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling (2017, background): “In a separate study, the TracerX consortium recently reported a comprehensive analysis of mutational heterogeneity using deep multi-region exome sequencing of 327 tumor regions from 100 patients (28).”
• Intratumor heterogeneity: the Rosetta stone of therapy resistance (2020, background): “Initial results from this study show that ITH for copy number alterations and genomic instability are associated with increased risk of recurrence or death (Jamal-Hanjani et al., 2017).”